Category: Respiratory
-
PureTech’s stock rises as deupirfenidone shows promising results in IPF Phase II trial
New data from the ELEVATE IPF trial reveal strong, durable benefits of deupirfenidone in slowing lung function decline.
-
Rejuvenate Biomed starts Phase II trial for COPD-related sarcopenia drug
The company has dosed the first patient in a Phase II trial evaluating its lead compound, RJx-01.
-
Boehringer releases detailed data for two Phase III lung fibrosis trials
The Phase III trials, FIBRONEER-IPF and FIBRONEER-ILD, evaluated nerandomilast and met their primary endpoints.
-
Chiesi collaborates with WPCC to enhance COPD detection
The partnership seeks to alleviate the burden on primary care and A&E services through early diagnosis and evidence-based interventions.
-
Philips discontinues Tack endovascular system following Class I recall
The company plans to cease distribution of the Tack endovascular system, and has advised the customers to stop using the system.
-
Hyfe and Kyorin partner to launch chronic cough digital therapeutic in Japan
The companies will collaborate to develop and commercialize the prescription digital therapeutic in the Japanese market.
-
Boehringer Ingelheim eyes FDA approval for lung fibrosis therapy
The Phase III FIBRONEER-ILD trial evaluating the company’s lung fibrosis drug, nerandomilast, met its primary endpoint by improving lung function.
Latest posts
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Urologic Health secures $11 million for non-invasive bladder monitoring
Urologic Health raises $11million seed funding to advance a catheter-free bladder monitoring platform toward FDA clearance and US market entry.
-
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors
Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.
-
Beyond the Snapshot: Continuous physiologic monitoring in clinical trials
Vivalink’s CEO discusses how continuous physiologic monitoring is transitioning from a niche tool for early-stage feasibility studies to a core component of late-stage drug development.